Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues

Key Takeaways RDY posted Q1 earnings of 20 cents per ADS and $997M in sales; beats consensus Zacks estimates on both counts.Global Generics rose 10%, led by Europe's Nicotine Therapy and strong branded market performance.RDY and ALVO signed a global deal to co-develop a biosimilar to Merck's cancer drug Keytruda.Dr. Reddy's Laboratories Limited (RDY) reported first-quarter fiscal 2026 earnings of 20 cents per American Depositary Share (ADS), which beat the Zacks Consensus Estimate of 18 cents. The company r ...